Trial Profile
Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a treatment with Durvalumab in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC- A COMPARISON WITH A HISTORICAL CONTROL GROUP-- DuTRe-raD
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DURTRE-RAD
- 09 Nov 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 06 Jun 2023 Status changed from recruiting to discontinued.
- 06 Jun 2023 Interim results of feasibility analysis presented at the 59th Annual Meeting of the American Society of Clinical Oncology